Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws

DSpace/Manakin Repository

Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Heinonen, Mikko en_US
dc.date.accessioned 2012-06-07T20:38:50Z
dc.date.issued 2002 en_US
dc.identifier.citation Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws (2002 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852181
dc.description.abstract The purpose of this article is to highlight the main issues raised by the Food and Drug Administration’s (“FDAâ€) approval process relating to new drugs and the treatment of this process receives in the context of the Federal Securities Laws . The partial inspiration for this article has been the recent highly publicized case concerning ImClone Systems Incorporated – a case, which well exemplifies both the connection between the valuation of a biotech/medical company and the FDA’s approval process for new drugs, and also the huge effect of the approval process to the market’s valuation of the stock price. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject FDA en
dc.subject securities en
dc.subject disclosure en
dc.subject approval en
dc.subject ImClone en
dc.title Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T20:38:50Z

Files in this item

Files Size Format View
Heinonen.pdf 0bytes PDF View/Open
Heinonen.rtf 238.5Kb RTF file View/Open
Heinonen.html 199.5Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters